Patient leaflets
This article was originally published in The Tan Sheet
Executive Summary
Leaflets on drugs currently provided to patients do not provide information they value and find useful, according to researchers. In Health Technology Assessment, D.K. Raynor, Pharmacy Practice and Medicines Management Group, University of Leeds School of Healthcare, U.K., et al., say most people do not value written information they receive about drugs. Patients want to know about possible adverse events and require information to help decide whether to take a medicine. "The readability of medicines' information is important to patients, with concerns about complex language and poor visual presentation," Raynor et al. say. They included 64 papers after conducting a database search and tabulating results...
You may also be interested in...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: